Kiniksa Pharmaceuticals
KNSA
96 hedge funds and large institutions have $539M invested in Kiniksa Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 48 increasing their positions, 14 reducing their positions, and 7 closing their positions.
271% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 7
243% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 14
97% more capital invested
Capital invested by funds: $274M → $539M (+$265M)
25% more funds holding
Funds holding: 77 → 96 (+19)
23% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $848K
2.54% less ownership
Funds ownership: 86.75% → 84.21% (-2.5%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$17.5M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$12.6M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$11.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.7M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
+$8.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$19.7M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$6.91M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$2.36M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$1.31M |
| 5 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$1.01M |
KNSA Hedge Fund Activity: Q2 2020 in Review
96 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q2 2020, worth a combined $539M — up 97% from $274M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new KNSA positions and 7 closed out — a net gain of 19 holders — while 48 added to existing stakes and 14 trimmed.
The largest buyer was Ameriprise, adding an estimated $17.5M. The largest seller was ArrowMark Colorado Holdings, exiting entirely with an estimated $19.7M sold.
- 96 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q2 2020, up from 77 in Q1 2020.
- Funds reported $539M of Kiniksa Pharmaceuticals stock for Q2 2020, up 97% quarter-over-quarter.
- 26 funds opened new Kiniksa Pharmaceuticals positions in Q2 2020 and 7 closed out, a net change of +19 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q2 2020 was Ameriprise, an estimated $17.5M added.
- The largest Kiniksa Pharmaceuticals seller in Q2 2020 was ArrowMark Colorado Holdings, an estimated $19.7M sold.
Based on aggregated 13F filings for Q2 2020.